JAK1 and neoplasm: To assess the contribution of IFN signaling to Activin-A induced tumor growth, mice bearing YUMM3.3-Ctrl or YUMM3.3-βA tumors were treated with the JAK1/2 inhibitor Ruxolitinib or with empty vehicle control (DMSO).